Article | October 16, 2020

Enhancing The Stability, Survival And Performance Of Microbiota-Targeted Therapies And Other Microbiome-Based Products

By Hans Baer

Evonik

There are literally trillions of microorganisms that live in the human digestive system and are believed to affect our health. These microorganisms include countless types of bacteria, viruses and fungi. While most of the hundreds of bacteria that reside in the gut and have been studied are beneficial, some are pathogenic.

The development of microbiota-targeted therapies and other microbiome-based products creates significant opportunities to improve human health and well-being. Firstly, there are several diseases that are thought to be influenced by microbial processes that occur within the gut. This includes many types of cancer, as well as autoimmune disorders such as multiple sclerosis. The gut microbiome can also influence the effects of various drug products such as mental health therapeutics. Finally, improved microbiome targeting solutions may be the key to enhance patient care for a range of therapeutic areas.

As a global leader for oral drug delivery, Evonik has developed a broad, versatile portfolio of functional excipients, drug delivery technologies and services for formulation development and cGMP manufacturing that can create value for microbiota-targeted therapies and other microbiome-based products.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online